Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.65 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25942196 | 0.89 | GPBAR1 (0.65) | GPBAR1NR1H4HSD17B10KMT2ANPC1 | |
| SCHEMBL3645504 | 0.85 | NR1H4 (0.58) | NR1H4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL17358926 | 0.84 | GPBAR1 (0.50) | GPBAR1NR1H4HSD17B10KMT2ANPC1 | |
| SCHEMBL16697733 | 0.82 | GPBAR1 (0.62) | GPBAR1NR1H4HSD17B10KMT2ALMNA | |
| SCHEMBL30605724 | 0.82 | GPBAR1 (0.62) | GPBAR1NR1H4HSD17B10KMT2ALMNA | |
| SCHEMBL1930966 | 0.81 | KMT2A (0.48) | GPBAR1NR1H4KMT2ALMNAHTT | |
| SCHEMBL21195682 | 0.81 | NR1H4 (0.54) | NR1H4 | |
| SCHEMBL28326024 | 0.81 | GPBAR1 (0.45) | GPBAR1NR1H4HSD17B10KMT2AMEN1 | |
| SCHEMBL19899921 | 0.80 | NR1H4 (0.53) | NR1H4LMNAALDH1A1TSHRMAPT | |
| SCHEMBL24212391 | 0.79 | GPBAR1 (1.00) | GPBAR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | GPBAR1 9/4885NR1H4 3/4885HSD17B10 2510/4885 |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | GPBAR1 191/4885NR1H4 517/4885HSD17B10 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.